Skip to main content

Table 1 Tumor characteristics and treatment of patients with unresectable locally advanced sigmoid colon cancer

From: Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer

Case Sex/age (years) cTNM Involved structures Therapy prior to enrollmenta (response) RT (technique, Gy per faction) Concurrent chemotherapya Surgery Resection status ypTNM Adjuvant chemotherapya OS (ms)/status ECOG PS score
1 F/43 cT4bN2M0 Bladder, pelvic wall No 3D-CRT, 46/23 XELOX × 2 Colectomy R0 ypT0N0M0 XELOX × 5 49/FOD 1
2 M/63 cT4bN2M0 Bladder No VMAT, 50/25 XELOX × 2 Colectomy R0 ypT0N0M0 XELOX × 5 36/FOD 1
3 M/59 cT4aN1M0 No No VMAT, 50/25 XELOX × 2 Colectomy R0 ypT0N0M0 XELOX × 1 39/FOD 0
4 M/58 cT3N2M0 No No VMAT, 50/25 XELOX × 2 + Xeloda × 1 Colectomy R0 ypT0N0M0 No 33/FOD 0
5 M/43 cT4aN2M0 No No VMAT, 50/25 XELOX × 3 Colectomy R0 ypT3N0M0 XELOX × 5 30/FOD 1
6 M/50 cT4aN2M1 No No VMAT, 50/25 XELOX × 4 Colectomy R0 ypT3N0M1 FOLFIRI + C225 × 8 28/AWD 0
7 F/67 cT3N2M0 No No VMAT, 50/25 XELOX × 2 Colectomy R0 ypT2N0M0 No 36/FOD 0
8 M/67 cT4bN2M0 Bladder, ureter No VMAT, 50/25 XELOX × 2 Colectomy + partial cystectomy + partial ureterectomy R0 ypT4bN0M0 XELOX × 1 32/FOD 1
9 M/67 cT4aN1M1 No No VMAT, 50/25 XELOX × 4 Colectomy R0 ypT3N0M1 XELOX × 2 17/DOD
10 M/70 cT4aN1M1 No No VMAT, 50/25 XELOX × 4 Colectomy R0 ypT3N0M1 No 28/AWD 2
11 M/47 cT4aN1M0 No No VMAT, 50/25 XELOX × 4 Colectomy R0 ypT0N0M0 XELOX × 2 21/FOD 0
12 F/63 cT4bN0M0 Uterus, ureter No VMAT, 50/25 XELOX × 3 Colectomy + partial ureterectomy R0 ypT1N0M0 XELOX × 1 21/FOD 0
13 F/50 cT4aN2M0 No No VMAT, 50/25 XELOX × 4 Colectomy R0 YpT0N0M0 XELOX × 1 21/FOD 0
14 M/30 cT4bN1M0 Bladder Sigmoidostomy 3D-CRT,46/23 XELOX × 2 Colectomy + partial cystectomy R0 ypT0N0M0 XELOX × 5 35/FOD 0
15 M/49 cT4bN1M0 Iliac vessels, ureter, ileum Colostomy VMAT, 50/25 XELOX × 2 + Xeloda × 1 Colectomy + partial cystectomy + partial ileectomy R0 ypT3N0M0 XELOX × 2 36/FOD 1
16 F/66 cT4bN2M0 Bladder, uterus Colostomy 3D-CRT, 46/23 XELOX × 4 Colectomy R0 ypT3N0M0 No 36/FOD 0
17 M/52 cT4bN2M0 Bladder, ureter Colostomy 3D-CRT, 46/23 XELOX × 2 Colectomy R0 ypT3N0M0 XELOX × 4, xeloda × 2 36/FOD 0
18 M/44 cT4bN2M0 Bladder, pelvic wall Sigmoidostomy 3D-CRT, 46/23 XELOX × 2 Colectomy + biopsy R2 ypT4aN0M1 No 39/AWD 1
19 M/52 cT4bN2M0 Bladder Sigmoidostomy, mFOLFOX × 6 (SD) VMAT, 50/25 CPT11 + Xeloda × 2 Colectomy + partial cystectomy R0 ypT0N0M0 Xeloda × 1 36/FOD 1
20 M/67 cT4bN1M0 Bladder Sigmoidostomy, mFOLFOX × 4 (SD), FOLFOXIRI × 3 (SD) VMAT, 50/25 XELOX × 2 Colectomy + partial cystectomy R0 ypT3N0M0 39/FOD 1
21 M/74 cT4bN2M0 Bladder, abdominal wall XELOX × 4 (SD) VMAT, 50/25 XELOX × 2 Colectomy + partial cystectomy R0 ypT3N0M0 Xeloda × 2 41/FOD 0
  1. F female; M male; SD stable disease; RT radiotherapy; OS overall survival; ms months; ECOG PS Eastern Cooperative Oncology Group Performance Status; FOD free of disease; AWD alive with disease; DOD dead of disease; cTNM clinical tumor, node and metastasis stage; ypTNM pathologic tumor, node and metastasis stage after neoadjuvant therapy. mFOLFOX oxaliplatin, 5-fluorouracil and leucovorin; FOLFOXIRI 5-fluorouracil, leucovorin, irinotecan and oxaliplatin; XELOX capecitabine and oxaliplatin; CPT11 irinotecan.; 3D-CRT three-dimensional conformal radiotherapy; VMAT volumetric modulated arc therapy
  2. aThe chemotherapy is presented as the regimen × the number of cycles